Download PDF
Thromb Haemost 2015; 113(04): 671-673
DOI: 10.1160/TH14-12-1087
Invited Editorial Focus
Schattauer GmbH

The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists

Roldán Vanessa
1   Department of Hematology and Clinical Oncology, Hospital Universitario Morales Meseguer, University of Murcia, Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca (IMIB-Arrixaca), Murcia, Spain
,
Francisco Marín
2   Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca (IMIB-Arrixaca), Murcia, Spain
› Author Affiliations
Further Information

Publication History

Received: 27 December 2014

Accepted after minor revision: 18 January 2015

Publication Date:
24 November 2017 (online)

    Permissions and Reprints

 

 

  • reference

  • 1 Gallego P, Roldán V, Marin F. et al. SAME-TT2R2 score, time in therapeutic range and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014; 127: 1083-1088.
    CrossrefPubMedGoogle Scholar
  • 2 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: current status and respectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Gallagher a M, Setakis E, Plumb JM. et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-977.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Morgan CL, McEwan P, Tukiendorf A. et al. Warfarin treatment in patients with atrial fibrillation:observing outcomes associated with varying levels of INR control. Thromb Res 2009; 124: 37-41.
    CrossrefPubMedGoogle Scholar
  • 5 Wan Y, Heneghan C, Perera R. et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 01: 84-91.
    CrossrefPubMedGoogle Scholar
  • 6 Gallego P, Roldan V, Marín F. et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-1198.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Camm a J, Lip GYH, De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
    CrossrefPubMedGoogle Scholar
  • 8 National-Institute-for-Health-and-Care-Excellence. Atrial fibrillation: the management of atrial fibrillation. (Clinical guideline 180.). http://guidanceniceorguk/CG180 2014
    PubMedGoogle Scholar
  • 9 Cerezo-Manchado JJ, Rosafalco M, Antón AI. et al. Creating a genotype-based dosing algorithm for acenocoumarol steady dose. Thromb Haemost 2013; 109: 146-153.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Meckley LM, Gudgeon JM, Anderson JL. et al. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 2010; 28: 61-74.
    CrossrefPubMedGoogle Scholar
  • 11 Le Heuzey J-Y, Ammentorp B, Darius H. et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost 2014; 111: 833-841.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Husted S, de Caterina R, Andreotti F. et al. Nonvitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 2014; 111: 781-782.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 http://www.aemps.gob.es/medicamentosUsoHu mano/informesPublicos/docs/criteriosanticoagulantes-orales.pdf
    PubMed
  • 14 Azoulay L, Dell’Aniello S, Simon TA. et al. Initiation of warfarin in patients with atrial fibrillation:early effects on ischaemic strokes. Eur Heart J 2014; 35: 1881-1887.
    CrossrefPubMedGoogle Scholar
  • 15 Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010; 104: 1099-1105.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Kornej J, Apostolakis S, Bollmann A, Lip GYH. The emerging role of biomarkers in atrial fibrillation. Can J Cardiol 2013; 29: 1181-1193.
    CrossrefPubMedGoogle Scholar
  • 17 Poli D, Antonucci E, Testa S. et al. A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med 2014; 09: 443-447.
    CrossrefPubMedGoogle Scholar
  • 18 Lip GYH, Haguenoer K, Saint-Etienne C. et al. Relationship of the SAMe-TT2R2 score to poorquality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014; 146: 719-726.
    CrossrefPubMedGoogle Scholar
  • 19 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e419S-94S.
    CrossrefPubMedGoogle Scholar
  • 20 Lane DA, Lip GYH. Patient’s values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. ThrombHaemost 2014; 111: 381-383.
    PubMedGoogle Scholar
  • 21 Lahaye S, Regpala S, Lacombe S. et al. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2014; 111: 465-473.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Holbrook A, Schulman S, Witt DM. et al. Evidence-based management of anticoagulant therapy:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e152S-84S.
    CrossrefPubMedGoogle Scholar
  • 23 Dlott JS, George R a, Huang X. et al. National assessment of warfarin anticoagulation therapy for stroke revention in atrial fibrillation. Circulation 2014; 129: 1407-1414.
    CrossrefPubMedGoogle Scholar
  • 24 Clarkesmith DE, Pattison HM, Lip GYH. et al. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One 2013; 08: e74037.
    CrossrefPubMedGoogle Scholar
  • 25 Ansell J, Hollowell J, Pengo V. et al. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in pa the international study of anticoagulation management (ISAM). J Thromb Thrombolysis 2007; 23: 83-91.
    CrossrefPubMedGoogle Scholar
  • 26 Wallentin L, Yusuf S, Ezekowitz MD. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation:an analysis of the RE-LY trial. Lancet 2010; 376: 975-983.
    CrossrefPubMedGoogle Scholar
  • 27 Ho C-W, Ho M-H, Chan P-H. et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke 2015; 46: 23-30.
    CrossrefPubMedGoogle Scholar
  • 28 Kooistra H, Veeger N, Khorsand N. et al. Longterm quality of vitamin K antagonist treatment and clinical outcome after extreme overanticoagulation in a cohort of 14,777 AF and VTE patients. Thromb Haemost 2015; 113: 881-890.
    Article in Thieme ConnectPubMedGoogle Scholar